Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies. The study is enrolling in the dose expansion cohorts.
Miscellaneous, Phase I
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
Cetuximab, MK-3475, Pembrolizumab (MK-3475), TTX-080
Keedy, Vicki
International
Vanderbilt University
03-17-2022
Treatment
VICCMD2172
NCT04485013

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Subject with histological diagnosis of advanced/metastatic cancer

Age 18 years or older, is willing and able to provide informed consent

Evidence of measurable disease

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1



Exclusion Criteria:

History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody

Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study

Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy

History of severe autoimmune disease

Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: